Bioelectronic medical device company Systems Inc reported on Tuesday the receipt of a USD8m Series Seed investment from Sand Hill Angels, Astia Angels, Golden Seeds, HBS Angels, Sierra Angels, Lateral Capital, Skylight Investments, a physician network and individual investors.

The company has raised funds in a series of tranches, the most recent of which closed last week. The funds will be used for marketing and fall launch of its ClearUP Sinus Pain Relief.

ClearUP is clinically proven, FDA cleared and reportedly the only bioelectronic solution on the market that provides consumers with a drug free option to treat allergy-related sinus pain using microcurrent (low-level electrical stimulation). ClearUP's proprietary technology delivers microcurrent waveforms that stimulate the nerves under the skin of the cheek, nose and eyebrow bone. ClearUP will be available in mid-September without a prescription and priced at USD149, added the company.

Through initial investments in 2017 and 2018, the company completed product development and design, clinical studies, FDA clearance, production and early marketing.